Welcome to our dedicated page for Alvotech SEC filings (Ticker: ALVOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alvotech’s SEC filings document a foreign private issuer focused on developing and manufacturing biosimilar medicines. Recent Form 6-K reports furnish press releases, earnings materials and business updates covering its biosimilar portfolio, pharmacokinetic studies such as AVT80 compared with Entyvio (vedolizumab), manufacturing compliance matters and FDA inspection outcomes at the Reykjavik facility.
The filing record also describes incorporation by reference into Form F-3, Form F-3ASR and Form S-8 registration statements, together with governance disclosures such as executive team changes. These documents frame Alvotech’s regulatory, operating, capital-markets and reporting activity through current reports and related exhibits.
Alvotech closed a major equity financing, combining an underwritten public share offering with a concurrent private placement to raise total gross proceeds of about $165 million.
The company sold 26,066,667 ordinary shares in the public offering at $3.75 per share, including 3,400,000 shares from the underwriters’ full over-allotment option, generating roughly $98 million in gross proceeds. At the same price, it agreed to sell an additional 17,826,666 ordinary shares in a private placement expected to raise about $67 million, subject to customary closing conditions.
In total, the board approved the issuance of 43,893,333 new ordinary shares, after which Alvotech’s share capital will be 390,431,480 ordinary shares. The company plans to use the net proceeds to advance its biosimilar pipeline, support working capital and general corporate purposes, which may include R&D, commercialization activities, intellectual property protection, capital expenditures, partnerships, and potential debt repayment or refinancing.
Alvotech closed a major equity financing, combining an underwritten public share offering with a concurrent private placement to raise total gross proceeds of about $165 million.
The company sold 26,066,667 ordinary shares in the public offering at $3.75 per share, including 3,400,000 shares from the underwriters’ full over-allotment option, generating roughly $98 million in gross proceeds. At the same price, it agreed to sell an additional 17,826,666 ordinary shares in a private placement expected to raise about $67 million, subject to customary closing conditions.
In total, the board approved the issuance of 43,893,333 new ordinary shares, after which Alvotech’s share capital will be 390,431,480 ordinary shares. The company plans to use the net proceeds to advance its biosimilar pipeline, support working capital and general corporate purposes, which may include R&D, commercialization activities, intellectual property protection, capital expenditures, partnerships, and potential debt repayment or refinancing.
Alvotech has launched a major equity financing, combining an underwritten public offering and a concurrent private placement, and updated investors on key U.S. regulatory risks for several biosimilars. The company is selling 22,666,667 ordinary shares at $3.75 per share, with underwriters exercising in full a 3,400,000-share option, for expected net proceeds of about $91.20 million. In parallel, Alvotech agreed to a private placement of 17,826,666 ordinary shares at the same price, targeting gross proceeds of roughly $66.85 million, with that closing contingent on the offering.
The funds are intended to support development of its biosimilar portfolio and general corporate purposes. Alvotech also added a risk factor explaining that the FDA issued Complete Response Letters for AVT03, AVT05 and AVT06 due to deficiencies at its Reykjavik manufacturing facility. The company has resubmitted BLAs for AVT05 and AVT06, but warns that any further FDA concerns or reinspection findings could delay U.S. approvals and adversely affect its business and share price.
Alvotech is offering 22,666,667 ordinary shares at a public offering price of $3.75 per share pursuant to this prospectus supplement.
The underwriters have a 30-day option to purchase up to 3,400,000 additional ordinary shares. A concurrent private placement of 17,826,666 shares for gross proceeds of approximately $66.85 million was agreed with certain EEA investors and is conditioned on the closing of this offering.
Alvotech is offering 22,666,667 ordinary shares at a public offering price of $3.75 per share pursuant to this prospectus supplement.
The underwriters have a 30-day option to purchase up to 3,400,000 additional ordinary shares. A concurrent private placement of 17,826,666 shares for gross proceeds of approximately $66.85 million was agreed with certain EEA investors and is conditioned on the closing of this offering.
Alvotech is offering ordinary shares pursuant to a preliminary prospectus supplement dated June 15, 2026. The supplement is being filed from an existing shelf registration and describes a primary offering of ordinary shares, with an underwriting option to purchase additional shares.
The supplement discloses a related concurrent private placement to certain European professional clients at the public offering price, conditioned on this offering closing. The company reports 312,153,164 ordinary shares outstanding as of March 31, 2026, recent FDA activity including a Form 483 following a May 2026 inspection of its Reykjavik facility and resubmissions of BLAs for AVT05 and AVT06 on June 4, 2026.
Alvotech is offering ordinary shares pursuant to a preliminary prospectus supplement dated June 15, 2026. The supplement is being filed from an existing shelf registration and describes a primary offering of ordinary shares, with an underwriting option to purchase additional shares.
The supplement discloses a related concurrent private placement to certain European professional clients at the public offering price, conditioned on this offering closing. The company reports 312,153,164 ordinary shares outstanding as of March 31, 2026, recent FDA activity including a Form 483 following a May 2026 inspection of its Reykjavik facility and resubmissions of BLAs for AVT05 and AVT06 on June 4, 2026.
Alvotech has suspended and terminated its ATM Prospectus Supplement with Jefferies LLC, which had allowed potential open market issuances of its ordinary shares under an Open Market Sale agreement dated June 14, 2024. The underlying Sales Agreement remains in effect, but the company will not sell securities under it unless a new prospectus supplement or a new registration statement is filed.
Alvotech has suspended and terminated its ATM Prospectus Supplement with Jefferies LLC, which had allowed potential open market issuances of its ordinary shares under an Open Market Sale agreement dated June 14, 2024. The underlying Sales Agreement remains in effect, but the company will not sell securities under it unless a new prospectus supplement or a new registration statement is filed.
Alvotech reported Q1 2026 total revenues of $105.9 million, down from $132.8 million a year earlier, with Adjusted EBITDA of $24.4 million and a 57% gross margin. Statutory profit was $1.0 million, helped by finance income, but operating cash flow was a $60.4 million outflow, reducing cash to $63.8 million as of March 31, 2026.
Debt remains high with outstanding borrowings of about $1.31 billion. Management still guides for 2026 revenues of $650–$700 million and Adjusted EBITDA of $180–$220 million, assuming growing biosimilar uptake and new launches. The company concluded it remains a going concern but may need additional financing if cash generation lags.
Strategically, regulators accepted a Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio, with an FDA review period of up to six months. The EMA has also validated a marketing application covering AVT16 and AVT80, and Alvotech expanded commercial agreements and advanced multiple pipeline programs, including Eylea HD and Entyvio biosimilar candidates.
Alvotech reported Q1 2026 total revenues of $105.9 million, down from $132.8 million a year earlier, with Adjusted EBITDA of $24.4 million and a 57% gross margin. Statutory profit was $1.0 million, helped by finance income, but operating cash flow was a $60.4 million outflow, reducing cash to $63.8 million as of March 31, 2026.
Debt remains high with outstanding borrowings of about $1.31 billion. Management still guides for 2026 revenues of $650–$700 million and Adjusted EBITDA of $180–$220 million, assuming growing biosimilar uptake and new launches. The company concluded it remains a going concern but may need additional financing if cash generation lags.
Strategically, regulators accepted a Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio, with an FDA review period of up to six months. The EMA has also validated a marketing application covering AVT16 and AVT80, and Alvotech expanded commercial agreements and advanced multiple pipeline programs, including Eylea HD and Entyvio biosimilar candidates.
Alvotech filed a Form 6-K highlighting two corporate updates. The company confirmed that all draft resolutions at its 2026 Annual and Extraordinary General Meeting held on June 3, 2026 were approved, with detailed minutes and voting results to be posted on its AGM web portal.
Alvotech also announced resubmission to the U.S. FDA of Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2 mg. The resubmissions follow responses to a Post-Application Action Letter and a routine cGMP surveillance inspection at its Reykjavik facility, and the company expects a six-month FDA review. Alvotech already markets five biosimilars globally and has nine disclosed biosimilar candidates in development.
Alvotech filed a Form 6-K highlighting two corporate updates. The company confirmed that all draft resolutions at its 2026 Annual and Extraordinary General Meeting held on June 3, 2026 were approved, with detailed minutes and voting results to be posted on its AGM web portal.
Alvotech also announced resubmission to the U.S. FDA of Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea 2 mg. The resubmissions follow responses to a Post-Application Action Letter and a routine cGMP surveillance inspection at its Reykjavik facility, and the company expects a six-month FDA review. Alvotech already markets five biosimilars globally and has nine disclosed biosimilar candidates in development.
Alvotech reports that the U.S. FDA has completed a routine cGMP surveillance inspection of its Reykjavik, Iceland manufacturing facility, which ended on May 8, 2026 with the issuance of a Form 483. The company believes the observations can be addressed quickly and do not raise substantial issues with the site or its operations.
Alvotech states it is well positioned to resubmit the relevant Biologics License Applications during the current quarter, after final data are compiled, and continues to expect FDA approval for these BLAs during 2026. The company highlights that the inspection outcome supports the strength of cGMP fundamentals and recent site improvements.
Alvotech reports that the U.S. FDA has completed a routine cGMP surveillance inspection of its Reykjavik, Iceland manufacturing facility, which ended on May 8, 2026 with the issuance of a Form 483. The company believes the observations can be addressed quickly and do not raise substantial issues with the site or its operations.
Alvotech states it is well positioned to resubmit the relevant Biologics License Applications during the current quarter, after final data are compiled, and continues to expect FDA approval for these BLAs during 2026. The company highlights that the inspection outcome supports the strength of cGMP fundamentals and recent site improvements.
Alvotech reported a leadership change, announcing that General Counsel Tanya Zharov has asked to step down after six years with the company. She helped prepare Alvotech for public listings in several jurisdictions and attract international talent to Iceland.
Zharov plans a several-month handover period, continuing to support the company during the transition. She will also take on board responsibilities for Chairman Róbert Wessman’s holding companies, Aztiq and Flóki. Alvotech continues to focus on developing and manufacturing biosimilar medicines, with five biosimilars already approved and marketed in multiple global markets.
Alvotech reported a leadership change, announcing that General Counsel Tanya Zharov has asked to step down after six years with the company. She helped prepare Alvotech for public listings in several jurisdictions and attract international talent to Iceland.
Zharov plans a several-month handover period, continuing to support the company during the transition. She will also take on board responsibilities for Chairman Róbert Wessman’s holding companies, Aztiq and Flóki. Alvotech continues to focus on developing and manufacturing biosimilar medicines, with five biosimilars already approved and marketed in multiple global markets.
Alvotech reported strong 2025 growth with improving profitability and a detailed 2026 outlook. Total revenues reached $593 million, up 21% year-on-year, while adjusted EBITDA rose 27% to $137 million with a 23% margin and gross margin of 61%. The company moved to a net profit of $28 million from a large loss in 2024, supported by higher licensing revenue and favorable non-cash finance items. Cash and cash equivalents were $172 million as of December 31, 2025, and operating cash flow turned positive at $7 million. Several biosimilars, including AVT03, AVT05 and AVT06, were approved in the UK, European Economic Area and Japan, while Selarsdi, referencing Stelara, launched in the United States. For 2026, management guides for total revenues of $650–700 million and adjusted EBITDA of $180–220 million, driven by expansion of commercialized products and efficiency gains, and anticipates late-2026 U.S. approvals for four pending Biologics License Applications.
Alvotech reported strong 2025 growth with improving profitability and a detailed 2026 outlook. Total revenues reached $593 million, up 21% year-on-year, while adjusted EBITDA rose 27% to $137 million with a 23% margin and gross margin of 61%. The company moved to a net profit of $28 million from a large loss in 2024, supported by higher licensing revenue and favorable non-cash finance items. Cash and cash equivalents were $172 million as of December 31, 2025, and operating cash flow turned positive at $7 million. Several biosimilars, including AVT03, AVT05 and AVT06, were approved in the UK, European Economic Area and Japan, while Selarsdi, referencing Stelara, launched in the United States. For 2026, management guides for total revenues of $650–700 million and adjusted EBITDA of $180–220 million, driven by expansion of commercialized products and efficiency gains, and anticipates late-2026 U.S. approvals for four pending Biologics License Applications.